NAMPT and metabolic syndrome: Concerning the controversies regarding the association of visfatin with overweight/obesity, type 2 diabetes mellitus, insulin resistance (IR), metabolic syndrome and cardiovascular disease in published articles, a meta-analysis was performed suggesting that the use of visfatin may be a promising predictive tool for these disorders (7).